FDA granted priority review for a gene therapy, while the company Rocket was listed on the Nasdaq stock exchange.
1 report, 1 independent
Updated Jun 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted priority review for a gene therapy, while the company Rocket was listed on the Nasdaq stock exchange.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
- Belite Bio, Inc. is seeking priority review for a drug application from the FDA and disclosed stock sales via SEC filing.
- Argenx SE announced it is listed on Nasdaq and is seeking FDA priority review and approval.
- Rocket is utilizing Nasdaq for investor evaluation and the FDA reviewed Phase 2 efficacy data for its product RP-A501.
- FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.